{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:00:19Z","timestamp":1790168419312,"version":"4.1.0"},"reference-count":44,"publisher":"Norwegian Medical Association","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.26.0199","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:35:21Z","timestamp":1788791721000},"source":"Crossref","is-referenced-by-count":0,"title":["HER2-positiv brystkreft"],"prefix":"10.4045","volume":"146","author":[{"given":"Kathrine","family":"Vandraas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn","family":"Naume","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"S\u00e6tersdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egil","family":"Blix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref=1","unstructured":"Folkehelseinstituttet. \u00c5rsrapport 2025. Resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft. Oslo: Kreftregisteret, 2026. https:\/\/www.fhi.no\/contentassets\/824dcef630d445b591a2b564bc9eddf9\/arsrapport-2025-nasjonalt-kvalitetsregister-for-brystkreft.pdf Lest 18.6.2026."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Ohnstad\u00a0HO, Borgen\u00a0E, Falk\u00a0RS et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res 2017; 19: 120. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29137653&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs13058-017-0911-9","DOI":"10.1186\/s13058-017-0911-9"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Dawood\u00a0S, Broglio\u00a0K, Buzdar\u00a0AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19933921&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2008.19.9844","DOI":"10.1200\/JCO.2008.19.9844"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Tolaney\u00a0SM, Tarantino\u00a0P, Graham\u00a0N et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol 2023; 24: 273\u201385. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36858723&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1470-2045(23)00051-7","DOI":"10.1016\/S1470-2045(23)00051-7"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Slamon\u00a0DJ, Clark\u00a0GM, Wong\u00a0SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 1987; 235: 177\u201382. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3798106&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1126%2Fscience.3798106","DOI":"10.1126\/science.3798106"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Swain\u00a0SM, Shastry\u00a0M, Hamilton\u00a0E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 2023; 22: 101\u201326. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36344672&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41573-022-00579-0","DOI":"10.1038\/s41573-022-00579-0"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Cheng\u00a0X. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes (Basel) 2024; 15: 903. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39062682&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3390%2Fgenes15070903","DOI":"10.3390\/genes15070903"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Wolff\u00a0AC, Somerfield\u00a0MR, Dowsett\u00a0M et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol 2023; 41: 3867\u201372. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37284804&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.22.02864","DOI":"10.1200\/JCO.22.02864"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Rakha\u00a0EA, Tan\u00a0PH, Van Bockstal\u00a0MR et al. International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer: Focus on HER2-Low and Ultralow Categories. Mod Pathol 2026; 39: 100925. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41167529&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.modpat.2025.100925","DOI":"10.1016\/j.modpat.2025.100925"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Hudis\u00a0CA. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39\u201351. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17611206&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMra043186","DOI":"10.1056\/NEJMra043186"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Loi\u00a0S, Michiels\u00a0S, Salgado\u00a0R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544\u201350. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24608200&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fannonc%2Fmdu112","DOI":"10.1093\/annonc\/mdu112"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Perez\u00a0EA, Ballman\u00a0KV, Tenner\u00a0KS et al. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol 2016; 2: 56\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26469139&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamaoncol.2015.3239","DOI":"10.1001\/jamaoncol.2015.3239"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Franklin\u00a0MC, Carey\u00a0KD, Vajdos\u00a0FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317\u201328. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15093539&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1535-6108(04)00083-2","DOI":"10.1016\/S1535-6108(04)00083-2"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Baselga\u00a0J, Cort\u00e9s\u00a0J, Kim\u00a0SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109\u201319. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22149875&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1113216","DOI":"10.1056\/NEJMoa1113216"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Scheuer\u00a0W, Friess\u00a0T, Burtscher\u00a0H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19934333&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1158%2F0008-5472.CAN-08-4597","DOI":"10.1158\/0008-5472.CAN-08-4597"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Lambert\u00a0JM, Morris\u00a0CQ. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Adv Ther 2017; 34: 1015\u201335. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28361465&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs12325-017-0519-6","DOI":"10.1007\/s12325-017-0519-6"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Verma\u00a0S, Miles\u00a0D, Gianni\u00a0L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783\u201391. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23020162&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1209124","DOI":"10.1056\/NEJMoa1209124"},{"key":"ref=18","unstructured":"Modi\u00a0S, Jacot\u00a0W, Yamashita\u00a0T et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35665782&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa2203690"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Saura\u00a0C, Modi\u00a0S, Krop\u00a0I et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 2024; 35: 302\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38092229&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.annonc.2023.12.001","DOI":"10.1016\/j.annonc.2023.12.001"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Bachelot\u00a0T, Romieu\u00a0G, Campone\u00a0M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14: 64\u201371. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23122784&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1470-2045(12)70432-1","DOI":"10.1016\/S1470-2045(12)70432-1"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Geyer\u00a0CE, Forster\u00a0J, Lindquist\u00a0D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733\u201343. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17192538&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa064320","DOI":"10.1056\/NEJMoa064320"},{"key":"ref=22","unstructured":"Murthy\u00a0RK, Loi\u00a0S, Okines\u00a0A et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597\u2013609. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31825569&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1914609"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Duchnowska\u00a0R, Loibl\u00a0S, Jassem\u00a0J. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treat Rev 2018; 67: 71\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29772459&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ctrv.2018.05.004","DOI":"10.1016\/j.ctrv.2018.05.004"},{"key":"ref=24","unstructured":"Piccart-Gebhart\u00a0MJ, Procter\u00a0M, Leyland-Jones\u00a0B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659\u201372. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16236737&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa052306"},{"key":"ref=25","unstructured":"Romond\u00a0EH, Perez\u00a0EA, Bryant\u00a0J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673\u201384. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16236738&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa052122"},{"key":"ref=26","unstructured":"von Minckwitz\u00a0G, Huang\u00a0CS, Mano\u00a0MS et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617\u201328. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30516102&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa1814017"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Slamon\u00a0DJ, Leyland-Jones\u00a0B, Shak\u00a0S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783\u201392. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11248153&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJM200103153441101","DOI":"10.1056\/NEJM200103153441101"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Swain\u00a0SM, Kim\u00a0SB, Cort\u00e9s\u00a0J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461\u201371. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=23602601&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1470-2045(13)70130-X","DOI":"10.1016\/S1470-2045(13)70130-X"},{"key":"ref=29","unstructured":"Swain\u00a0SM, Miles\u00a0D, Kim\u00a0SB et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 519\u201330. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32171426&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1470-2045(19)30863-0"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Haji\u00a0F, Hurvitz\u00a0SA. Can Women With HER2-Positive Metastatic Breast Cancer Be Cured? Clin Breast Cancer 2021; 21: 526\u201331. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34334312&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.clbc.2021.06.012","DOI":"10.1016\/j.clbc.2021.06.012"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s\u00a0J, Kim\u00a0SB, Chung\u00a0WP et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022; 386: 1143\u201354. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35320644&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa2115022","DOI":"10.1056\/NEJMoa2115022"},{"key":"ref=32","unstructured":"Helsedirektoratet. Nasjonal faglig retningslinje. Brystkreft \u2013 handlingsprogram https:\/\/www.helsedirektoratet.no\/retningslinjer\/brystkreft--handlingsprogram Lest 18.6.2026."},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Hurvitz\u00a0SA, Hu\u00a0Y, O'Brien\u00a0N et al. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 2013; 39: 219\u201329. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22658319&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ctrv.2012.04.008","DOI":"10.1016\/j.ctrv.2012.04.008"},{"key":"ref=34","unstructured":"Harbeck\u00a0N, Ciruelos\u00a0E, Jerusalem\u00a0G et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med 2024; 30: 3717\u201327. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39271844&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41591-024-03261-7"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Swain\u00a0SM, Schneeweiss\u00a0A, Gianni\u00a0L et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol 2017; 28: 761\u20138. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28057664&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fannonc%2Fmdw695","DOI":"10.1093\/annonc\/mdw695"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Ewer\u00a0MS, Vooletich\u00a0MT, Durand\u00a0JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16258084&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.2005.13.300","DOI":"10.1200\/JCO.2005.13.300"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Sawaya\u00a0H, Sebag\u00a0IA, Plana\u00a0JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011; 107: 1375\u201380. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21371685&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.amjcard.2011.01.006","DOI":"10.1016\/j.amjcard.2011.01.006"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Swain\u00a0SM, Nishino\u00a0M, Lancaster\u00a0LH et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022; 106: 102378. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35430509&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ctrv.2022.102378","DOI":"10.1016\/j.ctrv.2022.102378"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Sawaki\u00a0M, Taira\u00a0N, Uemura\u00a0Y et al. Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. J Clin Oncol 2020; 38: 3743\u201352. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32936713&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200%2FJCO.20.00184","DOI":"10.1200\/JCO.20.00184"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Miles\u00a0D, Baselga\u00a0J, Amadori\u00a0D et al. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 2013; 142: 89\u201399. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24129974&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs10549-013-2710-z","DOI":"10.1007\/s10549-013-2710-z"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Vandraas\u00a0KF, Hjorth\u00a0S, Trewin-Nybr\u00e5ten\u00a0CB et al. Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment. Int J Cancer 2026; 158: 633\u201341. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40892038&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fijc.70120","DOI":"10.1002\/ijc.70120"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Hjorth\u00a0S, Vandraas\u00a0KF, Trewin-Nybr\u00e5ten\u00a0CB et al. Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently. Breast Cancer Res Treat 2026; 215: 54. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41498846&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs10549-025-07888-z","DOI":"10.1007\/s10549-025-07888-z"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Conte\u00a0P, Schneeweiss\u00a0A, Loibl\u00a0S et al. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer 2020; 126: 3132\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32286687&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fcncr.32873","DOI":"10.1002\/cncr.32873"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Dowling\u00a0GP, Daly\u00a0GR, Keelan\u00a0S et al. Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis. Clin Breast Cancer 2023; 23: 847\u2013855.e2. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37775347&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.clbc.2023.09.005","DOI":"10.1016\/j.clbc.2023.09.005"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:00:26Z","timestamp":1790164826000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2026\/08\/klinisk-oversikt\/her2-positiv-brystkreft"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.26.0199","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}